Data on the fate of MACS® MicroBeads intramyocardially co-injected with stem cell products

Paula Müller; Ralf Gaebel; Heiko Lemcke; Gustav Steinhoff; Robert David

doi:10.1016/j.dib.2017.06.035

Data on the fate of MACS® MicroBeads intramyocardially co-injected with stem cell products

Data Brief. 2017 Jun 24:13:569-574. doi: 10.1016/j.dib.2017.06.035. eCollection 2017 Aug.

Authors

Paula Müller^{1

2}, Ralf Gaebel^{1

2}, Heiko Lemcke^{1

2}, Gustav Steinhoff^{1

2}, Robert David^{1

2}

Affiliations

¹ Reference and Translation Center for Cardiac Stem Cell Therapy (RTC), Department of Cardiac Surgery, Rostock University Medical Center, Schillingallee 69, 18057 Rostock, Germany.
² Department Life, Light and Matter of the Interdisciplinary Faculty at Rostock University, Albert-Einstein Straße 25, 18059 Rostock, Germany.

Abstract

The data presented in this article are related to the research article "Intramyocardial Fate and Effect of Iron Nanoparticles co-injected with MACS® purified Stem Cell Products" (Müller et al., 2017) [1]. This article complements the cellular localization of superparamagnetic iron dextran particles (MACS® MicroBeads) used for magnetic activated cell sorting (MACS®). Data evaluate the time-dependent detachment of these nanoparticles from CD133⁺ haematopoietic stem cells (HSCs) and CD271⁺ mesenchymal stem cells (MSCs). Furthermore, the influence of these stem cells as well as of nanoparticles on cardiac remodeling processes after myocardial infarction (MI) was investigated.

Keywords: Cardiovascular regeneration; Haematopoietic stem cells (HSCs); MACS® MicroBeads; Magnetic activated cell sorting (MACS®); Mesenchymal stem cells (MSCs); Stem cell therapy.